Program
FWY003
A development code.
In Novartis's pipeline, Factor B inhibitor
. Its studies are mostly in Geographic Atrophy, led by Novartis.
Furthest: phase 2, since Feb 24, 20261 company-led study, 1 open or runningNext primary completion: Aug 21, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Feb 24, 2026 | Feb 24, 2026 | Aug 21, 2029phase 2 · NCT07441642 |
- Named in Novartis’s own pipeline as
FWY003
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2026First study: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationFirst studyNCT07441642 · 272 planned · United States, Argentina, Australia and more
Ahead
- Aug 21, 2029Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07441642
TargetBeta
“Factor B inhibitor”the company's pipeline, read by Claude · source
Other programs on CFB
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Argentina, Australia and more | 2 | Recruiting | Aug 21, 2029 | 272 |
How it is read
Names in the registry
- “FWY003”, 1 entry
Codes read as this program: FWY003.
Conditions, from the studies’ own filings
- Geographic Atrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.